BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Beach

  Cianna Medical Launches Comprehensive Support Program to Support Health Systems’ Mission of ‘Moving Beyond Wires’ for Breast Tumor Localization

  The company introduced the program at the 2017 San Antonio Breast Cancer Symposium taking place from December 5-9, 2017, in San Antonio, Texas.

  December 5, 2017

   · 

  4 min read
• Biotech Bay

  Frost & Sullivan Industry Experts Host Interactive Briefing Discussing the Technologies Driving Cancer, Diabetes and Obesity Management

  The webinar will offer expert insight from Frost & Sullivan’s Vandana Iyer.

  December 5, 2017

   · 

  2 min read
• Biotech Bay

  Light Polymers Announces Next-Generation OLED Polarizer Technology

  Light Polymers is announcing a next-generation circular polarizer for OLED displays based on lyotropic liquid crystal technology. Light Polymers’ proprietary nanochemistry creates a circular polarizer at 45 µm, thinner than any competitive offering.

  December 5, 2017

   · 

  2 min read
• Drug Development

  Positive Preclinical Data from Xenon’s XEN901 Epilepsy Program to be Presented at the 71st American Epilepsy Society Annual Meeting

  XEN901 is a potent, selective Nav1.6 sodium channel inhibitor being developed by Xenon for the treatment of epilepsy.

  December 5, 2017

   · 

  4 min read
• Business

  Sunesis’ CEO Resigns, Effective Dec. 31, 2017

  Mr. Swisher will remain with the Company as a Strategic Advisor to the Board of Directors through 2018.

  December 5, 2017

   · 

  4 min read
• Business

  TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board

  Dr. Daniels was Senior Vice President at Bristol-Myers Squibb until 2014.

  December 5, 2017

   · 

  2 min read
• Business

  Peregrine Pharmaceuticals to Report Financial Results for Second Quarter of Fiscal Year 2018 After Market Close on December 11, 2017

  Peregrine’s senior management will discuss financial results for the second quarter and review recent corporate developments.

  December 5, 2017

   · 

  2 min read
• Business

  Opiant Pharmaceuticals Reports Fiscal First Quarter 2018 Financial Results

  For the quarter ended October 31, 2017, Opiant generated revenue of approximately $22,000, compared to approximately $1.1 million in the quarter ended October 31, 2016. T

  December 5, 2017

   · 

  5 min read
• Policy

  Adamis Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to the FDA for New Product Candidate for the Treatment of Opioid Overdose

  damis intends to develop a naloxone injection product candidate utilizing the same patented Symject syringe drug delivery platform used in Adamis’ approved Symjepi product.

  December 5, 2017

   · 

  4 min read
• Biotech Bay

  Dynavax Technologies Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

  Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $18.40 per share.

  December 5, 2017

   · 

  1 min read